As we head into the final day of ESMO Congress 2025, here are some of our snaps from the weekend! And if you haven't already, you can read our recent press release here https://lnkd.in/gfzQ3JSM #ESMO2025
Iksuda Therapeutics
Biotechnology Research
Newcastle Upon Tyne, Tyne and Wear 4,281 followers
Creating class-leading ADCs with enhanced tumor specificity
About us
Through our highly experienced ADC Research & Development Team, we are building a pipeline of class-leading ADCs with superior therapeutic index (TI) for difficult-to-treat cancers. Our approach is to develop the best ADC for any given target or tumor sub-type rather than 'technology-driven ADCs'. All our ADCs incorporate tumor-selective release & activation of the most relevant payload according to mechanism, optimizing anti-cancer efficacy and enhancing patient safety.
- Website
-
http://www.iksuda.com
External link for Iksuda Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Newcastle Upon Tyne, Tyne and Wear
- Type
- Privately Held
- Specialties
- Antibody-Drug Conjugates, PermaLink™, Conjugation Chemistry, Cancer research, ADCs, Drug Development, Therapeutics, Antibodies, Toxins, Cancer Treatment, ADC Stability, Antibody Drug Conjugate, Drug Discovery, Biotechnology, Preclinical, Bioconjugation, Organic Synthesis, Clinical, Cell Biology, Chemistry, and Licencing
Locations
-
Primary
Get directions
The Biosphere, Draymans Way
Newcastle Helix
Newcastle Upon Tyne, Tyne and Wear NE4 5BX, GB
Employees at Iksuda Therapeutics
Updates
-
Another exciting announcement from the Iksuda team! 👇 Iksuda presents encouraging IKS014 Phase 1 data at ESMO Read all about it here https://lnkd.in/gfzQ3JSM #ESMO2025
-
Iksuda to present IKS014 Phase 1 data at ESMO See below for more details 👇 https://lnkd.in/gzkYb9Wx #ESMO2025
-
Iksuda Therapeutics are pleased to share that our paper "IKS04, a CanAg-Targeting Antibody-Drug Conjugate with Pyrrolobenzodiazepine, Shows Enhanced Efficacy with Unconjugated Antibody Coadministration in Animal Models" has been published via AACR Journals. For more details, visit: https://lnkd.in/gjEEVrpF
-
Members of the Iksuda Team have attended the 5th Crick International Cancer Conference this week. We've met a lot of interesting people and attended a lot of great talks. The conference continues today - if you see any of the team, say hello! 👋 #CrickCancerConf
-
-
Congratulations to Bryony Moss, Zoë Jukes & Rachel Hui who all took part in the Great North Run on Sunday and absolutely smashed their fundraising targets! 🎉 A huge well done ladies! And well done to everyone who took part. 👏 #CancerResearchUK #CHUF #GNR2025 #GreatNorthRun
-
-
Good Luck to everyone running in the Great North Run this weekend! 🏃♀️ 🏃♂️ A special shout out to our very own Bryony Moss, Rachel Hui & Zoë Jukes all running for brilliant causes! Best of luck ladies! If you want to show your support consider donating: Cancer Research UK: https://lnkd.in/gdJXctFm Children's Heart Unit Fund (CHUF): https://lnkd.in/gDpGAFFK #CancerResearchUK #CHUF #GNR2025 #GreatNorthRun
-
-
Iksuda Therapeutics reposted this
Don't miss your chance to better predict ADC clinical activity, improve the translational mismatch, and successfully translate your ADC into the clinic at World ADC San Diego! Take a look at the top sessions on our brand-new Preclinical & Translational Medicine Streams: https://ter.li/kj59ol Confirmed speakers include: AbbVie, Bicycle Therapeutics, Byondis, Exelixis, Iksuda Therapeutics, SOTIO Biotech, Tagworks Pharmaceuticals, University of Michigan, Avidity Biosciences, Inc., Daiichi Sankyo US, Genentech, Pfizer, and many more.